Founders at Work: Tahoe Therapeutics

​Building Frontier Datasets to Power the Virtual Cell

​Generation of large scale single-cell datasets are now integral to the vision of the Virtual cell. At Tahoe, we are leading a generation of frontier scale datasets across diverse perturbations to i) develop programs from unbiased datasets ii) enable modeling of the cell states.

​Johnny Yu is a Co-founder and the Chief Scientific Officer at Tahoe (formerly Vevo Therapeutics). He's focused on building and scaling technologies such as Mosaic that allow for high-throughput in vivo drug screening for AI-powered drug discovery. His work sits at the intersection of large-scale single-cell data generation initiatives for drug development across multiple cancer indications. He trained at UCSF with Dr. Hani Goodarzi and Dr. Kevan Shokat (both Cofounders of Tahoe) and holds a PhD from UCSF. Prior to UCSF, he was at the Broad Institute and Biogen.